摘要
目的观察肝癌经导管动脉栓塞化疗(TACE)术后采取干扰素(IFN)抗病毒治疗的临床疗效。方法 90例中晚期原发性肝癌患者,随机分为观察组与对照组,各45例。对照组患者实施TACE术,观察组患者在对照组基础上给予IFN抗病毒治疗。观察比较两组患者的临床疗效、治疗前后外周血T淋巴细胞水平及不良反应发生情况。结果观察组治疗总有效率为95.56%,对照组治疗总有效率为82.22%,两组比较差异有统计学意义(P<0.05)。观察组治疗后CD4^+、CD4^+/CD8^+均较治疗前升高(P<0.05),治疗前后CD8^+比较差异无统计学意义(P>0.05);对照组治疗后CD4^+、CD4^+/CD8^+均较治疗前降低(P<0.05),治疗前后CD8^+比较差异无统计学意义(P>0.05);治疗后观察组CD4^+、CD4^+/CD8^+均高于对照组(P<0.05),治疗后两组患者CD8^+比较差异无统计学意义(P>0.05)。观察组患者出现不良反应27例(60.00%),对照组患者出现不良反应23例(51.11%),两组比较差异无统计学意义(χ~2=0.720, P=0.396>0.05)。结论肝癌患者TACE术后采取IFN抗病毒治疗,能够提高患者的治疗有效率,改善患者的免疫功能,用药安全。
Objective To observe the clinical efficacy of interferon(IFN) antiviral therapy after transcatheter arterial chemoembolization(TACE) in patients with liver cancer. Methods A total of 90 patients with advanced primary liver cancer were randomly divided into observation group and control group, with 45 cases in each group. The control group received TACE, and the observation group received antiviral therapy with IFN on the basis of control group. Observation and comparison were made on clinical efficacy, peripheral blood T lymphocyte level before and after treatment and occurrence of adverse reations between the two groups. Results The observation group had total treatment effective rate as 95.56%, which was 82.22% in the control group, and the difference was statistically significant(P<0.05). After treatment, the observation group had higher CD4^+ and CD4^+/CD8^+ than those before treatment(P<0.05), and there was no statistically significant difference in CD8^+ before and after treatment(P>0.05). The control group had lower CD4^+ and CD4^+/CD8^+ after treatment than those before treatment(P<0.05), and there was no statistically significant difference in CD8^+ before and after treatment(P>0.05). After treatment, the observation group had higher CD4^+ and CD4^+/CD8^+ than the control group(P<0.05). Both groups had no statistically significant difference in CD8^+(P>0.05). The observation group had 27 cases of adverse reactions(60.00%), which was 23 cases(51.11%) in the control group, and the difference was not statistically significant(χ~2=0.720, P=0.396>0.05). Conclusion Antiviral therapy with IFN after TACE in patients with liver cancer can improve the treatment efficiency, immune function and medication safety.
出处
《中国现代药物应用》
2019年第7期74-76,共3页
Chinese Journal of Modern Drug Application
关键词
原发性肝癌
动脉化疗栓塞
干扰素
疗效
Primary liver cancer
Arterial chemoembolization
Interferon
Efficacy
